Cannabix Technologies Releases Images of Beta 2.0 Cannabix Marijuana Breathalyzer

Market News

Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to release images of its Beta 2.0 Cannabix Marijuana Breathalyzer. New images of the device can be viewed at www.cannabixtechnologies.com.

Cannabix and University of Florida make significant strides in developing benchtop FAIMS technology into a portable Cannabix Marijuana Breathalyzer


Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”)
developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to release images of its Beta 2.0 Cannabix Marijuana Breathalyzer. New images of the device can be viewed at www.cannabixtechnologies.com.
Cannabix has been using a methodical iterative product development process to develop its marijuana breathalyzer.  Using this method, the product is developed in several prototype stages with each stage used to advance the product to subsequent stages.   Cannabix has systematically moved the development of the Cannabix Marijuana Breathalyzer from a concept stage to its Beta 2.0 prototype. The following is a chronology of development highlights:

  • August 2015-Cannabix entered into a research and option agreement to develop a cutting-edge breath detection sensor based upon high-field ion mobility coupled with mass spectrometry in collaboration with the Yost Research Group at the University of Florida.  The Yost Research Group, a world leader and pioneer in the development of high-field asymmetric waveform ion mobility spectrometry, known as FAIMS.  Cannabix and The Yost Research Group began working together to identify Tetrahydrocannabinol (THC- the psychoactive component of marijuana that causes intoxication) in ultra low ranges using highly a sensitive FAIMS-mass spectrometer benchtop system. The Company entered into a definitive license agreement with the University of Florida for US Patent 8,237,118 in the summer of 2016 which provided the Company exclusive worldwide rights in the area of breath analysis of controlled substances.
  • June 2016-Cannabix Scientists and Dr. Rick Yost at the University of Florida developed a standalone desktop-sized “Beta 1.0” FAIMS based device with a proprietary configurable high voltage power supply which operated with conventional power sources. The FAIMS cell employed in “Beta 1.0” device was 4X smaller than the prior benchtop version and had achieved a 10X reduction in power supply size, which allowed for a drastically smaller footprint.  The Beta 1.0 included a power supply that was readily configurable for ongoing testing and was designed to integrate with a non-radioactive ionization source.
  • October 19, 2016- Cannabix developed its “Beta 2.0” Cannabix Marijuana Breathalyzer with major advances in the design and size of the device, including:  greater sensitivity, improved performance by the square waveform generator and a much smaller size for all components.  The Beta 2.0 design included features to allow for the addition of a rechargeable battery and touch screen and the device is approximately 10 times smaller than the Beta 1.0 device. Preliminary lab tests of the FAIMS device coupled with quadrupole ion trap mass spectrometry have shown lower levels of detection for THC standards than were achieved in past testing.
  • November 11, 2016- Cannabix provides the first images of the Cannabix Marijuana Breathalyzer “Beta 2.0” device.  Images show components housed in a durable compact black box which has been reduced in size to be a portable device. The device encompasses the latest chip technology to improve speed performance, FAIMS detection technology, conventional battery and updated square wave generator. Cannabix believes that the Beta 2.0 Cannabix Marijuana Breathalyzer which utilizes FAIMS detection technology is the most sensitive and scientifically proven method of detection of volatile compounds found at trace levels in exhaled breath.

Read full press release.
Click here to visit the Cannabix Technologies Inc. website.

The Conversation (0)
×